Clinical Trials Logo

Evan Syndrome clinical trials

View clinical trials related to Evan Syndrome.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06014775 Recruiting - Treatment Clinical Trials

Anti-CD38 Antibody Treating Evans Syndrome

2023-D-ES
Start date: December 2023
Phase: Phase 2
Study type: Interventional

A single-center, open-label, off-label use investigator-initiated clinical study with safety run-in to explore the clinical activity and safety of Anti-CD38 Antibody in adult ES patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including immunosuppressive agents, Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are suitable.

NCT ID: NCT04993885 Recruiting - Clinical trials for Immune Thrombocytopenia

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.

NCT ID: NCT04915482 Recruiting - Clinical trials for Connective Tissue Diseases

TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Start date: June 6, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This prospective, open-label, nonrandomized, multicenter clinical trial aims at comparing the efficacy and safety of combined use of TPO-RAs with low-dose anti-CD20 monoclonal antibody vs. the best available therapy(BAT)in adult immune thrombocytopenia with autoantibodies failed (due to intolerance or resistance) to first-line treatment.